Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme and a member of the serine hydrolase family. It plays a central role in the degradation of fatty acid amides, which are endogenous signaling lipids involved in various physiological processes. FAAH is particularly important for terminating the signaling actions of bioactive lipids such as anandamide (an endocannabinoid), oleamide (a sleep-inducing lipid), and other N-acylethanolamines. Because inhibition or genetic deletion increases endogenous cannabinoid tone without directly activating cannabinoid receptors, targeting FAAH is considered promising for developing analgesics or anxiolytics with potentially fewer side effects than direct receptor agonists.
Hydrolyzes fatty acid amides into their corresponding fatty acids and amines, thereby regulating their levels and biological activity. Inhibition of FAAH increases levels of bioactive fatty acid amides.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fatty Acid Amide Hydrolase (FAAH).